Expansion to OptiMAL collaboration agreement

Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces an expansion to the collaboration agreement (the "Agreement") with the National Cancer Institute ("NCI").

The Company has entered into a variation to the Agreement with NCI, pursuant to which the collaboration between the parties will be expanded to include the humanisation by Fusion of several of the NCI's existing camelid nanobodies. Camelid nanobodies are small antibodies derived from camel species that offer benefits in bi-specific therapies and Chimeric Antigen Receptor ("CAR") therapies.

NCI, part of the US National Institutes of Health, is the US federal government's principal agency for cancer research and training. Pursuant to the Agreement, details of which were announced by the Company on 28 November 2023, Fusion has provided NCI with access to OptiMAL® for use in the discovery of novel antibodies against targets selected by Dr. Mitchell Ho's Lab at the NCI.

Richard Buick, CSO of Fusion Antibodies plc, commented: "We are excited to deploy our class leading humanisation technology to these nanobodies developed by Mitchell Ho's group at the NCI, as they have shown excellent activity in published models for CAR-T therapy. We look forward to being able to assist the NCI in their path to clinical success and to continuing to foster goodwill with the NCI in this wider capacity."

About Reach announcements